- Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
-
Ji Young Lim, Minjong Lee, Tae Hun Kim
-
J Liver Cancer. 2020;20(2):113-119. Published online September 30, 2020
-
DOI: https://doi.org/10.17998/jlc.20.2.113
-
-
3,875
Views
-
131
Downloads
-
Abstract
PDF
- In the Barcelona Clinic Liver Cancer staging system, intermediate stage hepatocellular carcinoma (HCC) is defined as large multinodular tumors without vascular invasion or extrahepatic spread in an asymptomatic patient with good performance status. Intermediate stage HCC includes various subgroups and it is characterized by extensive heterogeneity. Current guidelines recommend transarterial chemoembolization (TACE) as the standard treatment modality for patients with intermediate stage HCC. Although TACE provides improved survival benefits compared with supportive care for patients with intermediate stage HCC, all of them are not good candidates for TACE. TACE refractoriness is another obstacle to effective treatment of patients with intermediate stage HCC. Given that many studies recently reported improved survival in patients treated with hepatic resection over TACE, we reviewed the survival outcomes of TACE and hepatic resection as a treatment strategy of intermediate stage HCC.
- A Case of Advanced Hepatocellular Carcinoma with Long-term Post-progression Survival under Repeated Transarterial Chemoembolization after Sorafenib Failure
-
Jihyun Lee, Hwi Young Kim, Yong Jin Jung, Tae Hun Kim, Kwon Yu
-
J Liver Cancer. 2017;17(1):82-87. Published online March 31, 2017
-
DOI: https://doi.org/10.17998/jlc.17.1.82
-
-
Abstract
PDF
- Hepatocellular carcinoma is the third leading cause of cancer related mortality worldwide.
Only 30% of patients are eligible for curative surgical resection at diagnosis. For patients with
advanced hepatocellular carcinoma with accompanying portal vein tumor thrombosis, Sorafenib
is recommended as first-line treatment. However, survival gain from sorafenib is unsatisfactory,
and there is no standard therapy for patients who are intolerable or refractory to sorafenib. Here
we report a case of a 52-year-old man who initially achieved partial response after sorafenib
treatment, but eventually showed disease progression and was treated subsequently with
transarterial chemoembolization (TACE). Multinodular recurrence occurred, but he was treated
with repeated TACE, and has survived for 4 years so far.
|